Cite
HARVARD Citation
Rizvi, N. et al. (n.d.). Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet oncology. 16 (3), pp. 257-265. [Online].